1.An experimental study of effect of curcumin on improvementof bone microarchitecture and bone quality inhigh-fat-diet C57BL/6J mice and its association with cathepsin K
Rufeng MA ; Lili WANG ; Jiacheng ZUO ; Ruyuan ZHU ; Haixia LIU ; Chenyue LIU ; Lin LI ; Beibei CHEN ; Dandan ZHAO ; Fangfang MO ; Jianzhao NIU ; Sihua GAO ; Dongwei ZHANG
Chinese Pharmacological Bulletin 2017;33(10):1446-1451
Aim To investigate the effect of curcumin against high-fat-diet induced C57BL/6J mice bone changes and the correlation between the expression of cathepsin K and curcumin.Methods Curcumin treated C57BL/6J mice had been on high fat diet for 12 weeks.The HE, Alizarin red S staining and Safranin O/fast green staining of femur were employed to evaluate bone microstructure, bone metabolism and bone development.The expressions of cathepsin K were assessed by Western blot and immunohistochemical staining.Results Histopathological results showed that curcumin could improve the destruction of trabecular bone structure, cartilage development and bone calcification.Biomechanical results proved that curcumin could improve the bone strength of the type 2 diabetic mice induced by high fat.The results of immunohistochemistry and Western blot assay indicated that curcumin could significantly inhibit the expression of cathepsin K in bone tissues of mice.Conclusion Curcumin can increase bone strength, improve bone microstructure, and enhance the degree of bone calcification, which may be achieved by inhibiting the expression of cathepsin K.
2.Effect of Anchang Decoction on intestinal flora and fecal calcitonin in rats with severe ulcerative colitis
Xuan YU ; Sihua LAI ; Dan GAO ; Zhiren ZHU ; Zebin TANG ; Linguang SI ; Pinghao NONG ; Pingliang SUN
International Journal of Traditional Chinese Medicine 2023;45(6):714-718
Objective:To investigate the effects of Anchang Decoction on intestinal microflora and faecal calprotectin (FC) in rats with severe ulcerative colitis based on probiotics.Methods:Totally 50 rats were taken to prepare a model of severe ulcerative colitis. The rats who successfully modeled were divided into model group, Anchang Decoction low-, medium-, high-dosage groups, Lizhu Changle group, and mesalazine group, with 5 rats in each group. Another 6 rats were set and the blank group. Lizhu Changle group received Lizhu Changle suspension (containing 50 million live bacteria/ml) for gavage; Anchang Decoction low-, medium-, high-dosage groups received Anchang Decoction 1, 5, 10 ml/(kg·d) for gavage; Mesalazine group received Mesalazine suspension (10.5 mg/100 g) for gavage. Rats in the blank group and model group were gavaged with the same volume of normal saline for 7 days. Body mass and disease activity index (DAI) before and after administration were measured. 16s rDNA of lactobacillus and bifidobacterium in feces of rats was detected. FC content of rats was detected by ELISA.Results:Compared with the model group, the weight of rats in each administration group increased ( P<0.05), DAI score decreased ( P<0.05), and the level of calprotectin in feces decreased ( P<0.05), and there was no significant difference in the levels of lactobacillus and bifidobacterium in each administration group ( P>0.05). Conclusion:Anchang Decoction can improve the intestinal micro-ecology by regulating the level of calprotectin in rats with severe ulcerative colitis, thereby playing a therapeutic role.
3.Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation.
Liang JIANG ; Yuting WANG ; Qian LI ; Zhengchao TU ; Sihua ZHU ; Sanfang TU ; Zhang ZHANG ; Ke DING ; Xiaoyun LU
Acta Pharmaceutica Sinica B 2021;11(5):1315-1328
Bcr-Abl threonine 315 to isoleucine 315 (T315I) gatekeeper mutation induced drug resistance remains an unmet clinical challenge for the treatment of chronic myeloid leukemia (CML). Chemical degradation of Bcr-Abl
4.Challenges and countermeasures of thoracic surgery in the epidemic of novel coronavirus pneumonia
XIE Dong ; WANG Sihua ; JIANG Gening ; LIAO Yongde ; ZHU Yuming ; ZHANG Lei ; XU Zhifei ; CHEN Keneng ; FANG Wentao ; GE Di ; TAN Lijie ; CHEN Xiaofeng ; LI Hecheng ; WU Chuangyan ; TONG Song ; LIU Zheng ; DING Xiangchao ; CHEN Jiuling ; CHENG Chao ; WANG Haifeng ; CHEN Chang
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery 2020;27(04):359-363
Since December 2019, a novel coronavirus (2019-nCoV, SARS-CoV-2) pneumonia (COVID-19) outbreak has occurred in Wuhan, Hubei Province, and the epidemic situation has continued to spread. Such cases have also been found in other parts of the country. The spread of the novel coronavirus pneumonia epidemic has brought great challenges to the clinical practice of thoracic surgery. Outpatient clinics need to strengthen the differential diagnosis of ground glass opacity and pulmonary plaque shadows. During the epidemic, surgical indications are strictly controlled, and selective surgery is postponed. Patients planning to undergo a limited period of surgery should be quarantined for 2 weeks and have a nucleic acid test when necessary before surgery. For patients who are planning to undergo emergency surgery, nucleic acid testing should be carried out before surgery, and three-level protection should be performed during surgery. Patients who are planning to undergo emergency surgery in the epidemic area should be confirmed with or without novel coronavirus pneumonia before operation, and perform nucleic acid test if necessary. Surgical disinfection and isolation measures should be strictly carried out. Among postoperative patients, cases with new coronavirus infection were actively investigated. For the rescue of patients with novel coronavirus infection, attention needs to be paid to prevention and treatment and related complications, including mechanical ventilation-related pneumothorax or mediastinal emphysema, and injury after tracheal intubation.